Cue Biopharma, Inc. is a innovative clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on advancing immune modulation therapies to address significant unmet needs in oncology, chronic infectious diseases, and autoimmune disorders. Leveraging its proprietary Immune Modulation platform, Cue Biopharma aims to enhance the efficacy of cancer immunotherapies and expand treatment options for patients. With its commitment to pioneering new biological therapies, the company is strategically positioned to become a leader in the rapidly evolving immuno-oncology landscape, demonstrating significant potential for growth and transformative impact within the field of immunotherapy. Show more

Location: 40 GUEST STREET, BOSTON, MA, UNITED STATES, 02135, Boston, MA, 02135, USA | Website: https://www.cuebiopharma.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

30.55M

52 Wk Range

$0.23 - $1.54

Previous Close

$0.36

Open

$0.35

Volume

723,403

Day Range

$0.33 - $0.37

Enterprise Value

20.47M

Cash

11.7M

Avg Qtr Burn

-9.024M

Insider Ownership

0.75%

Institutional Own.

24.22%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CUE-102 Details Recurrent Glioblastoma	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CUE-101 (IL-2) +/- pembrolizumab Details HPV+ head and neck squamous cell carcinoma (HNSCC)	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CUE-401 (Tolerogenic IL-2 Fusion) Details Autoimmune Diseases	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.